BridgeMD
New treatment option for Skin Infection
Official title Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
ClinicalTrials.gov ID: NCT05899140
What this study is testing
What is Clindamycin?
Clindamycin is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for skin infection.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (age ≥18 years);
- Need for a treatment (incision/drainage ± antibiotic treatment po or iv) of an SSTI;
- S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be...
- Onset of symptoms within the last 4 weeks;
- Randomisation possible within 72 hours from collection of the initial culture
You likely can't join if
- Previous allergic reaction to clindamycin
- Previous antibiotic-associated diarrhea
- Previous study participation
- Pregnancy as confirmed by a beta-HCG rapid test.
- Started treatment with clindamycin prior to clinic presentation;
- Documented systemic antibiotic treatment within the previous 14 days
See the full eligibility criteria
- Adults (age ≥18 years);
- Need for a treatment (incision/drainage ± antibiotic treatment po or iv) of an SSTI;
- S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be the leading pathogen);
- Onset of symptoms within the last 4 weeks;
- Randomisation possible within 72 hours from collection of the initial culture
- Ability to conduct the follow-up visits either during admission or at home
- Initial culture collected within 48 hours of hospital admission
- Willingness to participate in the study.
- Previous allergic reaction to clindamycin
- Previous antibiotic-associated diarrhea
- Previous study participation
- Pregnancy as confirmed by a beta-HCG rapid test.
- Started treatment with clindamycin prior to clinic presentation;
- Documented systemic antibiotic treatment within the previous 14 days
- Co-administration of other protein synthesis inhibitors (e.g. macrolides, rifampicin, linezolid, aminoglycosides, tetracyclines, chloramphenicol);
- Co-administration of toxin inducers (trimethoprim-sulfamethoxazole)
- Severe illness (patient expected to die in the following 24 hrs);
- Chronically infected wounds (\>4 weeks of symptoms);
- Infections associated with any of the following (due to mixed infection): a) Human or animal bites;b) Prosthetic or implantable devices; c) Decubitus ulcers; d) Diabetic foot ulcers, infected ulcers secondary to...
- Hospital-acquired infection including post-surgical site infections
The study team makes the final eligibility decision.
Where it's taking place
- Masokori, Sierra Leone
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Masokori, Sierra Leone. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.